Nuzenio

Aligos Therapeutics Reports

Aligos Therapeutics Reports news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 5 publisher sources 100/100 entity strength

Latest news

Aligos Therapeutics reports Q2 EPS (14c), consensus ($1.38) - TipRanksTipRanks · Fri, 07 Aug 2026 00:58:37 GMTAligos Therapeutics, Inc. Q2 10-Q Filing: Financial Statements, Key Risks, and Company Overview 2026 - MinichartMinichart · Thu, 06 Aug 2026 22:30:00 GMTAligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 14:09:37 GMTAligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 12:11:09 GMTAligos Therapeutics (Nasdaq: ALGS) logs Q2 loss but lands $27.8M HBV license revenue - Stock TitanStock Titan · Thu, 06 Aug 2026 12:08:12 GMTAligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash - TradingViewTradingView · Thu, 06 Aug 2026 12:03:18 GMTAligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 12:00:00 GMTAligos Therapeutics to report results before markets open Aug. 6 - Stock TitanStock Titan · Thu, 30 Jul 2026 12:00:00 GMT

Timeline

Fri, 07 Aug 2026 00:58:37 GMTAligos Therapeutics reports Q2 EPS (14c), consensus ($1.38) - TipRanks
Thu, 06 Aug 2026 22:30:00 GMTAligos Therapeutics, Inc. Q2 10-Q Filing: Financial Statements, Key Risks, and Company Overview 2026 - Minichart
Thu, 06 Aug 2026 14:09:37 GMTAligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingView
Thu, 06 Aug 2026 12:11:09 GMTAligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary - TradingView
Thu, 06 Aug 2026 12:08:12 GMTAligos Therapeutics (Nasdaq: ALGS) logs Q2 loss but lands $27.8M HBV license revenue - Stock Titan
Thu, 06 Aug 2026 12:03:18 GMTAligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Aligos Therapeutics Reports.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.